The latter events are more frequently associated with treatment with anti-PD-1 antibodies (Pembrolizumab and Nivolumab), while colitis and hypophysitis with anti-CTLA-4 antibodies (Ipilimumab). This evidence concerns the gene CTLA4 and hypophysitis.